Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome.
Phase of Trial: Phase III
Latest Information Update: 25 Jun 2018
At a glance
- Drugs Olmesartan medoxomil (Primary) ; Amlodipine
- Indications Essential hypertension
- Focus Biomarker; Therapeutic Use
- Acronyms VAMOS
- Sponsors Daiichi Sankyo Europe
- 10 Jun 2017 Biomarkers information updated
- 29 Apr 2012 Secondary endpoint results presented at the 22nd European Meeting on Hypertension.
- 28 Apr 2012 Planned number of patients changed from 60 to 70 as reported by European Clinical Trials Database record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History